Response surface optimization of the heparosan N-deacetylation in producing bioengineered heparin

Journal of Biotechnology

Volumn 156, Issue 3, 2011, Pages 188-196

  Wang, Zhenyu ^a,c   Li, Jennifer ^a   Cheong, Samantha ^a   Bhaskar, Ujjwal ^a,c   Akihiro, Onishi ^c   Zhang, Fuming ^a,c   Dordick, Jonathan S ^a,c   Linhardt, Robert J ^a,b,c  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^b Research Rensselaer Polytechnic Institute   (United States)

^c RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Bioengineered; Factorial design; Heparin; Heparosan; N deacetylation

Indexed keywords

BIOENGINEERED; FACTORIAL DESIGN; HEPARIN; HEPAROSAN; N-DEACETYLATION;

ACETYLATION; DESIGN; ESCHERICHIA COLI; MOLECULAR WEIGHT; OPTIMIZATION; POLYSACCHARIDES; SURFACE PROPERTIES; SYNTHESIS (CHEMICAL);

SURFACES;

GLYCOSAMINOGLYCAN POLYSULFATE; HEPARIN;

ARTICLE; BIOENGINEERING; CHEMICAL REACTION; DEACETYLATION; ESCHERICHIA COLI; MOLECULAR WEIGHT; PRIORITY JOURNAL; REACTION TIME; TEMPERATURE;

ACETYLATION; BIOMEDICAL ENGINEERING; DISACCHARIDES; ESCHERICHIA COLI; HEPARIN; MOLECULAR WEIGHT; TEMPERATURE;

ESCHERICHIA COLI;

EID: 80054091089     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2011.08.013     Document Type: Article

References (30)

1. Agnelli G., Piovella F., Buoncristiani P., Severi P., Pini M., D'Angelo A., Beltrametti C., Damiani M., Andrioli G.C., Pugliese R., Iorio A., Brambilla G. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N. Engl. J. Med. 1998, 339:80-85.
2. Aslan N., Cebeci Y. Application of Box-Behnken design and response surface methodology for modeling of some Turkish coals. Fuel 2006, 86:90-97.
3. Barrington S., Kim J.W. Response surface optimization of medium components for citric acid production by Aspergillus niger NRRL 567 grown in peat moss. Bioresour. Technol. 2008, 99:368-377.
4. Box G.E., Behnken D.W. Some new three level designs for the study of quantitative variables. Technometrics 1960, 2:455-475.
5. Casu B., Grazioli G., Razi N., Guerrini M., Naggi A., Torri G., Oreste P., Tursi F., Zoppetti G., Lindahl U. Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr. Res. 1994, 263:271-284.
6. Chen J., Avci F.Y., Munoz E.M., McDowell L.M., Chen M., Pedersen L.C., Zhang L., Linhardt R.J., Liu J. Enzymatic redesigning of biologically active heparan sulfate. J. Biol. Chem. 2005, 280:42817-42825.
7. Chen J., Jones C.L., Liu J. Using an enzymatic combinatorial approach to identify anticoagulant heparan sulfate structures. Chem. Biol. 2007, 14:986-993.
8. Dahlback B. Blood coagulation. Lancet 2000, 355:1627-1632.
9. Erbing C., Granath K., Kenne L., Lindberg B. A new method for the N-deacetylation of carbohydrates. Carbohydr. Res. 1976, 47:C5-C7.
10. Ferreira S.L., Bruns R.E., Ferreira H.S., Matos G.D., David J.M., Brandao G.C., da Silva E.G., Portugal L.A., dos Reis P.S., Souza A.S., dos Santos W.N. Box-Behnken design: an alternative for the optimization of analytical methods. Anal. Chim. Acta 2007, 597:179-186.
11. Gerard, N., Pierre, B., 1961. Process of purifying heparin, and product produced therefrom US patent #2989438.
12. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bisio A., Capila I., Lansing J.C., Guglieri S., Fraser B., Al-Hakim A., Gunay N.S., Zhang Z.Q., Robinson L., Buhse L., Nasr M., Woodcock J., Langer R., Venkataraman G., Linhardt R.J., Casu B., Torri G., Sasisekharan R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat. Biotechnol. 2008, 26:669-675.
13. Guerrini M., Bisio A., Torri G. Combined quantitative (1)H and (13)C nuclear magnetic resonance spectroscopy for characterization of heparin preparations. Semin. Thromb. Hemost. 2001, 27:473-482.
14. Jandik K.A., Kruep D., Cartier M., Linhardt R.J. Accelerated stability studies of heparin. J. Pharm. Sci. 1996, 85:45-51.
15. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., Lansing J.C., Sriranganathan N., Zhao G.L., Galcheva-Gargova Z., Al-Hakim A., Bailey G.S., Fraser B., Roy S., Rogers-Cotrone T., Buhse L., Whary M., Fox J., Nasr M., Dal Pan G.J., Shriver Z., Langer R.S., Venkataraman G., Austen K.F., Woodcock J., Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 2008, 358:2457-2467.
16. Kuberan B., Beeler D.L., Lech M., Wu Z.L., Rosenberg R.D. Chemoenzymatic synthesis of classical and non-classical anticoagulant heparan sulfate polysaccharides. J. Biol. Chem. 2003, 278:52613-52621.
17. Kuberan B., Lech M.Z., Beeler D.L., Wu Z.L., Rosenberg R.D. Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide. Nat. Biotechnol. 2003, 21:1343-1346.
18. Lindahl U., Li J.P., Kusche-Gullberg M., Salmivirta M., Alaranta S., Veromaa T., Emeis J., Roberts I., Taylor C., Oreste P., Zoppetti G., Naggi A., Torri G., Casu B. Generation of " Neoheparin" from E. coli K5 capsular polysaccharide. J. Med. Chem. 2005, 48:349-352.
19. Linhardt R.J. Heparin: an important drug enters its seventh decade. Chem. Ind. 1991, 2:45-50.
20. Linhardt R.J., Toida T. Heparin oligosaccharides: new analogues - development and applications. Carbohydrates in Drug Design 1997, 277-341. Marcel Dekker, New York. Z.B. Witczak, K.A. Nieforth (Eds.).
21. Liu H., Zhang Z., Linhardt R.J. Lessons learned from the contamination of heparin. Nat. Prod. Rep. 2009, 26:313-321.
22. Ma C., Wang A., Qin J., Li L., Ai X., Jiang T., Tang H., Xu P. Enhanced 2,3-butanediol production by Klebsiella pneumoniae SDM. Appl. Microbiol. Biotechnol. 2009, 82:49-57.
23. Manzoni M., Bergomi S., Rollini M. Influence of the culture conditions on extracellular lyase activity related to K5 polysaccharide. Biotechnol. Lett. 2000, 22:81-85.
24. Myers R.H., Montgomery D.C. Response Surface Methodology - Process and Product Optimization Using Designed Experiments 2002, John Wiley & Sons, New York, NY. 2nd ed.
25. Okuyama, T., Yoshida, K., Sakurai, K., Ogura, T., Horie, K., Tawada, A., Hara, T., 1975. Method of separating and recovering mucopolysaccharides from connective tissue of animals. US patent #3862003.
26. Vidic, H.-J., 1981. Process for the preparation of heparin. US patent #4283530.
27. Wang Z., Dordick J.S., Linhardt R.J. Escherichia coli K5 heparosan fermentation and improvement by genetic engineering. Bioeng. Bugs 2011, 2:63-67.
28. Wang Z., Ly M., Zhang F., Zhong W., Suen A., Hickey A.M., Dordick J.S., Linhardt R.J. E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol. Bioeng. 2010, 107:964-973.
29. Wang Z., Yang B., Zhang Z., Ly M., Takieddin M., Mousa S., Liu J., Dordick J.S., Linhardt R.J. Control of the heparosan N-deacetylation leads to an improved bioengineered heparin. Appl. Microbiol. Biotechnol. 2011, 91:91-99.
30. Zhang Z.Q., McCallum S.A., Xie J., Nieto L., Corzana F., Jimenez-Barbero J., Chen M., Liu J., Linhardtt R.J. Solution structures of chemoenzymatically synthesized heparin and its precursors. J. Am. Chem. Soc. 2008, 130:12998-13007.